Chapter Update Summary

10/18/2021

  • Updated by substantial reorganization of the chapter with new added information

10/18/2021

10/18/2021

10/18/2021

10/18/2021

10/18/2021

10/18/2021

10/18/2021

10/18/2021

10/18/2021

  • New information on switching from efavirenz 600 mg daily to efavirenz 400 mg daily

3/17/2020

3/17/2020

3/17/2020

  • Results from the TANGO study showing comparable virologic efficacy when switching to dolutegravir/lamivudine vs continued tenofovir AF–based 3-drug or 4-drug ART

3/17/2020

  • Data from 2 studies showing efficacy of switching a virologically suppressive regimen to long-acting injectable cabotegravir plus rilpivirine: ATLAS and FLAIR

10/12/2018

5/2/2018

2/5/2018

1/18/2018

  • FDA approval of the fixed-dose coformulation dolutegravir/rilpivirine for use as a complete switch regimen in patients with virologic suppression on stable ART for ≥ 6 months with no history of treatment failure and no RAVs to either drug

11/14/2016

2/18/2016

10/14/2015

7/31/2015

  • New section on maintenance switching to dual therapy of boosted PI and NRTI to maintain virologic suppression including 3 randomized clinical trials showing noninferiority to triple-drug regimen maintenance (SALT, ATLAS-M, OLÉ trials)
  • Higher rate of virologic rebound through Week 48 in patients switched from a triple-drug regimen to dual boosted atazanavir and raltegravir
  • 3Using a strict definition of virologic failure, Week 48 results of the randomized PROTEA trial showed that switching from virologically suppressive antiretroviral therapy to darunavir/ritonavir monotherapy was inferior to boosted darunavir plus 2 NRTIs for virologic efficacy, but a post hoc analysis elucidated that the loss of efficacy was distinctive to patients with CD4+ cell nadirs < 200 cells/mm
  • Week 96 data from the LATTE study demonstrate similar virologic efficacy with cabotegravir and rilpivirine–based, NRTI-sparing treatment simplification strategy vs continued treatment with efavirenz plus 2 NRTIs
  • Week 96 data from the randomized, open-label MODAt study confirmed earlier results that switching virologically suppressed patients from atazanavir/ritonavir plus 2 NRTIs to atazanavir/ritonavir monotherapy was inferior to continuing atazanavir/ritonavir plus 2 NRTIs in an intent-to-treat virologic efficacy analysis that treated cases of regimen reintensification as failures

3/12/2015

5/21/2014

4/9/2014

  • New phase III results from the STRATEGY-PI and the STRATEGY-NNRTI trials of switching virologically suppressed patients to once-daily cobicistat/elvitegravir/emtricitabine/tenofovir DF

12/23/2013

6/7/2013

3/13/2013

10/4/2011

2/4/2011

10/18/2010

  • Updated data from the ARIES trial of switching from atazanavir/ritonavir to unboosted atazanavir
  • New data on switching from a boosted PI to raltegravir
  • New data on lipid improvements upon switching from abacavir/lamivudine to tenofovir/emtricitabine
  • New data on switching NNRTIs in virologically suppressed patients due to toxicity

3/19/2010

  • Updated with published data from the SWITCHMRK trial